(Q40845939)

24 September 2017

1 reference

title

Biologic agents and immunotherapy in rheumatoid arthritis. Progress and perspective (English)

1 reference

24 September 2017

1 reference

Wallis WJ

1

1 reference

24 September 2017

Furst DE

series ordinal

2

1 reference

24 September 2017

Strand V

series ordinal

3

1 reference

24 September 2017

Keystone E

series ordinal

4

1 reference

24 September 2017

language of work or name

1 reference

1 August 1998

1 reference

Rheumatic Diseases Clinics of North America

24 September 2017

published in

1 reference

24 September 2017

volume

24

1 reference

24 September 2017

issue

3

1 reference

24 September 2017

page(s)

537-565

1 reference

Peptide competition for antigen presentation

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Interleukin-6 in biology and medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Mechanisms of monoclonal antibody-facilitated tolerance induction: a possible role for the CD4 (L3T4) and CD11a (LFA-1) molecules in self-non-self discrimination

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Cytokine production in culture by cells isolated from the synovial membrane

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Characterization of T-cell receptor alpha beta repertoire in synovial tissue from different temporal phases of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

T lymphocyte clones illuminate pathogenesis and affect therapy of experimental arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Expectation bias in rheumatoid arthritis clinical trials. The anti-CD4 monoclonal antibody experience

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Pathways of destruction in metacarpal and metatarsal joints of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Apoptosis in rheumatoid arthritis synovium

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Therapeutic effect of the anti-Fas antibody on arthritis in HTLV-1 tax transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

The progression of the inflammation in established collagen-induced arthritis can be altered by treatments with immunological or pharmacological agents which inhibit T cell activities

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Tumor necrosis factor receptor-mediated signaling pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Anti-CD4 antibody treatment of patients with rheumatoid arthritis: I. Effect on clinical course and circulating T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Limited T-cell receptor beta-chain heterogeneity among interleukin 2 receptor-positive synovial T cells suggests a role for superantigen in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Humanised monoclonal antibody therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Amelioration of antigen-induced arthritis in rabbits treated with monoclonal antibodies to leukocyte adhesion molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Interleukin-6 activity in paired samples of synovial fluid. Correlation of synovial fluid interleukin-6 levels with clinical and laboratory parameters of inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Bypassing the antigen to control rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Th1/Th2 cytokine balance in arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Adhesion molecules: a rheumatologic perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. A double-blind, placebo-controlled trial with open-label extension.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Apoptosis in rheumatoid arthritis: a novel pathway in the regulation of synovial tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

New insights into the pathogenesis and treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Interleukin-10 suppresses the development of collagen type II-induced arthritis and ameliorates sustained arthritis in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151. Clinical results and immunopharmacologic effects in an open study, including repeated administration

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

T-cell activation: integration of signals from the antigen receptor and costimulatory molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Soluble tumor necrosis factor receptors in human inflammatory synovial fluids

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Models of T cell anergy: is there a common molecular mechanism?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

DAB486IL-2 fusion toxin in refractory rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Tumor necrosis factor, other cytokines and disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Effects of oral administration of type II collagen on rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

A randomized, double-blind study comparing twenty-four-week treatment with recombinant interferon-gamma versus placebo in the treatment of rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Treatment of collagen-induced arthritis in rats with a monoclonal antibody against the α/β T cell antigen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

Increased frequency of V beta 17-positive T cells in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970025-9

7 January 2021

10.1016/S0889-857X(05)70025-9

Identifiers

DOI

1 reference

24 September 2017

1 reference